CTNM — Contineum Therapeutics Share News
0.000.00%
Last trade - 00:00PREVIEW: Johnson & Johnson earnings expected to decline in Q3
US STOCKS ON THE MOVE-Microsoft, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Microsoft, C3.ai, Salesforce, Bristol Myers
Contineum tumbles as Bristol's partial trial win raises dose doubts
NASDAQ RESUMED AT 04:00 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:50 PM
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
Contineum falls as J&J-partnered depression drug fails mid-stage trial
Live Markets: From Ozempic Face to K-Beauty Factories: The Next Beauty Bet
Live Markets: Autumn in New York: Factory expansion slows, input prices at multi-year highs - Empire State
Live Markets: US stock indexes swing lower as oil, yields jump
Contineum, J&J's depression drug fails to meet mid-stage trial goal (updated)
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Contineum Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-GE Aerospace
Contineum Therapeutics slides after upsized $90 million stock sale
Brief: Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share